Circulating tumor cells (CTCs) are tumor cells that detach from the primary tumor and travel in the bloodstream, spreading from the original tumor to other locations, leading to cancer metastasis. These cells exist in peripheral blood of cancer patients and detection of CTCs can help to determine the process of metastasis. In contrast with other blood cells, the number of CTCs is very rare in blood which makes them difficult to detect.

Cancer stem cells (CSCs) are cancer cells that have all the classical properties of normal stem cells. Specifically, they are able to both give rise to more copies of themselves and to give rise to all cell types found in the cancer.
According to the research, the most potential market in the main countries of circulating tumor cells (CTCs) and cancer stem cells (CSCs) industry is China, determined by the rising level of medical care. Besides, South America, Asia-Pacific should also be focused by the investors. They are the potential consumers of circulating tumor cells (CTCs) and cancer stem cells (CSCs).
The CellSearch test is the only FDA-approved test for CTC assessment. For the moment, the products are not comprehensive, and technologies are not stable.
Morbidity and mortality rate of cancer is rising at a faster speed worldwide and thus prevention of cancer and cancer treatment is grabbing attention of cancer researchers globally. Stem cells and cell therapy have shown significant potential to treat cancer effectively.

According to this study, over the next five years the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market will register a 22.5% CAGR in terms of revenue, the global market size will reach USD 21700 million by 2024, from USD 6420 million in 2019. In particular, this report presents the global revenue market share of key companies in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) business, shared in Chapter 3.

This report presents a comprehensive overview, market shares and growth opportunities of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market by product type, application, key companies and key regions.

This study considers the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) value generated from the sales of the following segments-

Segmentation by product type- breakdown data from 2014 to 2019 in Section 2.3; and forecast to 2024 in section 10.7.
CellSearch
Others
Segmentation by application- breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 10.8.
Breast Cancer Diagnosis and Treatment
Prostate Cancer Diagnosis and Treatment
Colorectal Cancer Diagnosis and Treatment
Lung Cancer Diagnosis and Treatment
Other Cancers Diagnosis and Treatment

This report also splits the market by region- Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report- Breakdown data in in Chapter 3.
Janssen
Qiagen
Advanced Cell Diagnostics
ApoCell
Biofluidica
Clearbridge Biomedics
CytoTrack
Celsee
Fluxion
Gilupi
Cynvenio
On-chip
YZY Bio
BioView
Fluidigm
Ikonisys
AdnaGen
IVDiagnostics
Miltenyi Biotec
ScreenCell
Silicon Biosystems

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market size by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market by identifying its various subsegments.
Focuses on the key global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the size of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.